ANDA 216493, held by Hangzhou Zhongmei. Fondaparinux Sodium.
As of Nov 16, 2026, ANDA 216493 (Fondaparinux Sodium), held by Hangzhou Zhongmei, was first approved by FDA on Aug 19, 2024, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 19, 2024 | Original application | Approved | None posted |
| Fondaparinux Sodium2.5MG/0.5ML (2.5MG/0.5ML) · solution;subcutaneous | Fondaparinux Sodium | Discontinued |
| Fondaparinux Sodium5MG/0.4ML (5MG/0.4ML) · solution;subcutaneous | Fondaparinux Sodium | Discontinued |
| Fondaparinux Sodium7.5MG/0.6ML (7.5MG/0.6ML) · solution;subcutaneous | Fondaparinux Sodium | Discontinued |
| Fondaparinux Sodium10MG/0.8ML (10MG/0.8ML) · solution;subcutaneous | Fondaparinux Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters